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Background: Lung cancer remains one of the most prevalent forms of cancer. Radiotherapy, with or without other
therapeutic modalities, is an effective treatment. Our objective was to report on the use of radiotherapy for lung
cancer, its variability in our region, and to compare our results with the previous study done in 2004 (VARA-I) in our
region and with other published data.
Methods: We reviewed the clinical records and radiotherapy treatment sheets of all patients undergoing
radiotherapy for lung cancer during 2007 in the 12 public hospitals in Andalusia, an autonomous region of Spain.
Data were gathered on hospital, patient type and histological type, radiotherapy treatment characteristics, and
tumor stage.
Results: 610 patients underwent initial radiotherapy. 37% of cases had stage III squamous cell lung cancer and were
treated with radical therapy. 81% of patients with non-small and small cell lung cancer were treated with concomitant
chemo-radiotherapy and the administered total dose was≥ 60 Gy and≥ 45 Gy respectively. The most common
regimen for patients treated with palliative intent (44.6%) was 30 Gy. The total irradiation rate was 19.6% with significant
differences among provinces (range, 8.5-25.6%; p < 0.001). These differences were significantly correlated with the
geographical distribution of radiation oncologists (r = 0.78; p = 0.02). Our results were similar to other published data
and previous study VARA-I.
Conclusions: Our results shows no differences according to the other published data and data gathered in the study
VARA-I. There is still wide variability in the application of radiotherapy for lung cancer in our setting that significantly
correlates with the geographical distribution of radiation oncologists.
Keywords: Non-small cell lung cancer, Radiotherapy, Clinical practice patterns, Small cell lung cancerBackground
Lung cancer (LC) is a worldwide health problem [1]. In
Spain, approximately 20 000 new cases are reported each
year and 18 000 individuals die from this disease. LC is
the first cause of cancer mortality in men and the third
in women (after breast and colorectal carcinomas) [1].
The incidence in women is 6-fold lower than in men but
is increasing, as in other Western countries [2,3].
Non-small cell lung cancer (NSCLC) accounts for 80%
of all LCs, and the tumor load (stage) at the time of diag-
nosis is a critical factor for its clinical management [4].* Correspondence: aris.tovar@gmail.com
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reproduction in any medium, provided the orAccording to clinical evidence accumulated over the past
decades, optimal outcomes are obtained if tumors are
treated in early stages, when surgery is more feasible.
When this is not possible, there is a strong consensus that
a multidisciplinary approach is warranted [5]. Thus, clin-
ical guidelines recommend the combination of chemo-
therapy (CT) and radiotherapy (RT) in different schedules
for patients with tumor stage II, IIIA, and IIIB. CT is rec-
ommended for the majority of patients with stage IV LC,
depending on their performance status, and RT is used for
palliative treatment [6-8]. CT-RT is the standard treat-
ment for small cell lung cancer (SCLC) patients with lim-
ited disease. In general, preventive whole brain RT is
recommended after CT-RT. CT is the treatment of choicetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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in palliative treatments [6,7].
RT has proven to be an effective treatment in LC, with or
without other therapeutic modalities [1,9]. However, several
studies [10,11] have shown wide variations in its manage-
ment among hospitals, including differences in utilization
rate and schedules in both NSCLC and SCLC patients.
Variability in medical practice (VMP) can imply worse out-
comes, greater morbidity, higher social costs and lower
cost-effectiveness. For these reasons, there has been an in-
crease in VMP studies, which usually attempt to explain
any geographic variations in terms of the accessibility of hu-
man and technical resources. In many cases, however, dif-
ferences in the type of professional practice may play a role
in this variability [12,13].
We previously conducted a study that focused on the
RT utilization rate and the patterns of RT application in
patients with breast, lung, gynaecology and head and
neck cancer (Variability and Appropriateness of Radio-
therapy in Andalusia [VARA] project I) in Andalusian
public hospitals in 2004 [14]. This study attributed the
inter-hospital variability in RT management schedules,
doses, fractionations to the low treatment unit: inhabit-
ant ratio (three per million inhabitants) (r = 0.823/p =
0.001) and number of radiation oncologists (r = 0.888/p
< 0.001). In addition, we found the greatest variability in
RT for LC (for example, in NSCLC the administered
dose ≥60Gy ranged between 0% and 28,1% according to
the hospital). A program launched in 2004 to improve
regional RT resources led to ratio of 4.2 treatment units
per million inhabitants by 2006. The objective of the
present study was to describe the variations in LC man-
agement among regional cancer centers in Andalusia
during 2007.
Methods
A retrospective longitudinal study was conducted during
2007 in all of the 12 public hospitals that offered RT
treatments in Andalusia, an autonomous region of
Southern Spain with 8.4 million inhabitants. These cen-
ters are distributed among the eight provinces of the re-
gion, ensuring coverage of the whole population. Only
10% of the total care is delivered in private healthcare fa-
cilities in the region.
We reviewed the clinical records and treatment of all pa-
tients who received external beam RT as primary treatment
(after the diagnosis, excluding patients who receive RT for
relapse or progression of the disease after the first treat-
ment) for LC of any histological type or stage with radical
or palliative intent based on the treatment intent recorded
in the charts. Data were obtained from the hospital dis-
charge information system (Minimum Basic Data Set), hos-
pital cancer registries, and clinical management computer
systems linked to the RT equipment (Varis®, Lantis® andImpac® networks). Demographic information was obtained
from the Spanish National Statistics Institute (http://www.
ine.es) [15], and estimates of the incidence of cancer in
the Andalusian population and its distribution by histo-
logical type and stage were extrapolated from data from
the Population Cancer Registry of Granada [16] and
Carlos III Institute of Health, Madrid [2]. Trained re-
searchers supervised by the staff at each center obtained
patient data from the clinical records and individual treat-
ment records.
Study variables included characteristics of the hospital
(province, megavoltage units, and professionals), patient
(age, gender, histological type, performance status estimated
with Eastern Cooperative Oncology Group (ECOG) scale
or Karnofsky scale, weight loss, and co-morbidity), and
treatment (medical indication: therapeutic intent, total
doses, fractions, nodal irradiation, delay, days of treatment,
planning with 2D or 3D, electron linear accelerator or co-
balt 60 treatment, and adverse effects).
Statistical procedures. Descriptive outcomes are shown as
means, medians, standard deviations and confidence inter-
vals. The bivariate analysis was performed using chi-square
test and Student t-test. SPSS version 12.0 (SPSS, Chicago
IL) was used for statistical analyses. The significance level
was set at p < 0.05 and all tests were two-tailed.
Ethical considerations. This was a retrospective study
with no diagnostic or therapeutic implications. The re-
search was approved by the Andalusian Ethics Commit-
tee for Clinical Trials.
Results
Patients
Out of the 3051 diagnosed cases of LC during the study
period in the population of Andalusia, we collected data
on the 610 patients who received RT as primary treat-
ment for the disease. The majority of patients were male
(91%), and the median age was 65 years (65 ± 10.4 years);
37% of cases had squamous cell carcinoma, 17% adeno-
carcinomas, 15% large-cell undifferentiated carcinoma,
12% NSCLCs of other histologies, and 19% SCLC.
Missing data were related to performance status (47%),
co-morbidity (26%), weight loss (44%), and toxicity
(77%). However, 44% of cases (268 patients) had a good
performance (ECOG 0–1) and 60% showed a weight
loss ≤ 10%.
The patients were staged according to TNM 6th edi-
tion [17].
Hospital and treatments
The distribution of the results by province is shown in
Table 1.
Out of the 610 patients in the study, 58% were treated
with radical therapy (8% with adjuvant RT post-surgery)
and 42% were treated with palliative therapy. The diagnosis
Table 1 Distribution by province and proportion of patients treated with radical (R) or palliative intent (P)
Provinces LC patients treated with RT LC patients treated with RT (%) Patients diagnosed with LC RT rate (%)*
1 21 (R 7 P 14) 3 (R 33 P 67) 244 9
2 54 (R 40 P 14) 9 (R 74 P 26) 458 12
3 70 (R 32 P 38) 11 (R 46 P 54) 305 23
4 87 (R 77 P 10) 14 (R 89 P 11) 336 26
5 48 (R 28 P 20) 8 (R 58 P 42) 183 26
6 48 (R 39 P 9) 8 (R 81 P 19) 244 20
7 132 (R 76 P 56) 22 (R 58 P 42) 580 23
8 150 (R 57 P 93) 25 (R 38 P 62) 701 21
Total 610 (R 356 P 254) 100% (R 58 P 42) 3051 20
*Statistically significant difference p < 0.001.
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62% of the NSCLC patients had stage III disease, and 71%
of the SCLC patients had limited disease (Table 2).
Computed tomography-based RT treatment planning
was performed in 95.1% of cases, and linear accelerator
treatment was applied in 70.7%.
Associated CT was received by over half of the pa-
tients (sequential CT by 30.3%, concomitant CT by
34.34%, and both by 4.4%). As shown in Table 3, the
most common CT regimen was a platin (cisplatin or car-
boplatin) combined with taxol 24.5%, gemcitabine 14.2%
or vinorelbine 13.2% or etoposide 28.3%. Etoposide was
used in SCLC.
Radical radiotherapy in NSCLC
Radical RT was applied to 274 NSCLC patients, whose
characteristics (gender and age) were similar to those of
the whole series. Most of them had squamous cell carcin-
oma with an advanced stages; 58% had an ECOG of 0–1,
and 42% did not show a weight loss > 10%. A regimen of
≥60 Gy with standard fractionation (1.8-2 Gy per fraction)
was administered to 74% of the patients. The irradiation
field contained the mediastinal area in 81% of cases. The
interval between the ordering and commencement of the
treatment was <30 days in 49.7% of patients. CT associ-
ated with RT was the most common approach (sequential
in 32.6%, concomitant in 41.7%, and both in 5.1% of
cases). The CT schedule was a platin (cisplatin or carbo-
platin) with taxol, vinorelbine, or gemcitabine.Table 2 Distribution by stage and histology
NSCLC N = 494 (81%)
Stage N (%) radical N (%) palliative Total (%)
I 17 (6.2) 4 (2) 21 (4.2)
II 33 (12.1) 8 (3.7) 41 (8.3)
III 179(65.3) 125 (57) 304 (61.5)
IV 45 (16.4) 83 (37.3) 128 (26)
n = 610 274 (55.4) 220 (44.6) 494 (100)Radical radiotherapy in SCLC
Radical RT was applied to 82 SCLC patients, whose charac-
teristics (gender and age) were similar to those of the whole
series. The majority of patients had limited stage with good
performance status (ECOG 0–1 in 87%), although weight
loss was more frequent (57%). 97% of patients received
doses ≥45 Gy with standard fractionation RT; (only 9 pa-
tients underwent a hypofractionated schedule). RT treat-
ment was delayed for >30 days in 67%, probably due to the
CT treatment. All patients were treated with CT (sequen-
tial in 26%, and concomitant in 63%). All except four pa-
tients received cisplatin (or carboplatin) plus etoposide.
Table 4 summarizes the characteristics of radical RT
for NSCLC and SCLC.
Palliative radiotherapy (NSCLC and SCLC)
The majority of patients undergoing palliative RT were
diagnosed with NSCLC (86.6%), mainly squamous cell
carcinoma (39%); 44.8% were with advanced stages, 30%
had an ECOG of 2–4, and 44% showed weight loss.
The most frequent RT schedule (in 44.6% of these pa-
tients) was 30 Gy (10 fractions × 3 Gy per fraction)
(Table 5). CT was not received by almost 40% of these
patients. The interval from the consultancy to palliative
RT was <15 days in 40% of the patients.
Comparative study
Statistically significant differences among provinces were
found in the histology and stage of cancers and in RTSCLC N = 116 (19%)
Stage N (%) radical N (%) palliative Total (%)
Limited 82 (71) - 82 (71)
Extended - 34 (29) 34 (29)
82 (71) 34 (29) 116 (100)
Table 3 Associated chemotherapy and regimens
Associated chemotherapy Regimen
Patients (%) Patients (%)
NSCLC SCLC NSCLC SCLC
No 163 (33) 16 (14) CDDP + Taxol 15 (3) -
Sequential 153 (31) 35 (30) Carbo + Taxol 153 (31) -
Concomitant 153 (31) 59 (51) CDDP + GMZ 84 (17) 2 (2)
Both 25 (5) 6 (5) CDDP + VNB 84 (17) 2 (2)
Total 494 (100) 116 (100) CDDP + VP-16 15 (3) 53 (46)
Carbo + VP-16 15 (3) 52 (45)
Other 128 (26) 7 (5)
Total 494 (100) 116 (100)
CDDP = cisplatin; Carbo = carboplatin; VNB = vinorelbine; GMZ = gemcitabine; VP-16 = etoposide.
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(Tables 1 and 6).
Significant interprovincial differences in irradiation
rate were found (p < 0.001) and were significantly corre-
lated with the inter-provincial distribution of radiation
oncologists (r = 0.66; p = 0.004) (Table 1, Figure 1).
We could not correlate the variability in the histology
and stage of cancer with radiotherapy intent, fraction-
ation, associated CT or radiation rate.
When we compared our data with those gathered from
VARA-I study, we could observe an increase in total
dose administered in both NSCLC and SCLC (p < 0.01),
stage (only statistically significant in NSCLC, p > 0.01)
with slight increase in advanced stages in our study, and
patients treated with palliative intent (only statistically
significant in NSCLC, p = 0.028). After the program to
improve regional RT resources based on VARA-I results,
the radiation rate increased by 4% from 16% in 2004 to
20% in 2007 (p < 0.001) (Table 7).Table 4 Characteristics of radical radiotherapy in NSCLC
and SCLC patients
Radical radiotherapy in NSCLC
Histology (%) Stage (%) RT dose (%) RT delay (%) Associated
CT (%)
SCC 48.1 I 6.2 <60 Gy 26 <30 days 49.7 No 20.6
ADC 21.7 II 12.1 ≥60 Gy 74 ≥30 days 50.3 Seq 32.6
LCUC 17.5 III 65.3 Conc 41.7
Others 12.7 IV 16.4 Both 5.1
Radical radiotherapy in SCLC
RT dose (%) RT delay (%) Associated CT (%)
<45 Gy 3 <30 days 33 No 0
≥45 Gy 97 ≥30 days 67 Sequential 26
Concomitant 63
Both 11
SCC: squamous cell carcinoma, ADC: adenocarcinoma, LCUC: Large-cell
undifferentiated carcinoma. Seq: sequential, Conc: concomitant.Overall, our data were in agreement with other pub-
lished data (Table 8) [18-25].
Discussion
The role of RT as an effective treatment in LC is clearly
established in clinical practice guidelines [6-8]. Most of
the patients in this Spanish survey were male, as re-
ported previously in this and other countries; there has
been a progressive increase in LC incidence among
women in Spain, but it remains considerably lower than
in the USA [20,26,27].
The mean age at LC onset diagnosis is 65 years in our re-
gion, within the range of 63–67 years reported in other
Spanish series, and the majority of LC patients are diag-
nosed with NSCLC in an advanced stage [20,26,27]. The
most frequent histological type is squamous cell carcinoma,
although the incidence rates for adenocarcinoma show a
rising trend and may possibly become higher than those for
squamous cell carcinoma in the future [20,26,27].
Thus, our results were not different from other pub-
lished studies.
Majority (74%) of the NSCLC patients undergoing rad-
ical RT received ≥60 Gy with standard fractionation, and
the irradiation field contained the mediastinal area inTable 5 RT schedules for LC treated with palliative intent
Radiotherapy schedule Total (%)
Conventional fractionation (1.8-2 Gy) 16.5%
3 fractions x 400 cGy 0.4%
15 fractions x 300 cGy 10.3%
10 fractions x 300 cGy 44.6%
5 fractions x 400 cGy 12.9%
2 fractions x 850 cGy 9.9%
1 fraction x 800 cGy 1.8%
Hyperfractionation 0.4%
Other 3.2%
Table 6 Statistically significant differences among provinces
Province Histology (%) Stage (%)
SCC ADC LCUC Others NSCLC SCLC Early (I-II) Advanced (III-IV)
1 33.3 11.1 0 33.3 22.2 24.9 75.1
2 28.3 28.3 19.6 13 10.9 25 75
3 38.3 18.3 20 3.3 20 2 97.9
4 31.1 13.5 29.7 2.7 23 13 87
5 29.3 4.9 22 31.7 12.2 12.9 87.1
6 57.1 21.4 2.4 2.4 16.7 11.2 88.9
7 33.3 19.8 4.2 25 17.7 8.5 91.4
8 46.6 13.6 10.2 2.3 27.3 10.7 89.4
Province Fractionation (%) Associated CT (%)
Conventional (1.8-2 Gy) Other No Yes
1 50 50.1 47.1 52.9
2 63.9 36.2 30.4 69.6
3 45.9 54 15.5 84.4
4 90.7 9.4 13.9 86.1
5 54.8 45.3 56.1 43.9
6 92.9 7.2 10.8 89.2
7 46.9 52.9 47.9 52.2
8 53.8 46.2 31.9 68.2
SCC: squamous cell carcinoma, ADC: adenocarcinoma, LCUC: Large-cell undifferentiated carcinoma. NSCLC: non small cell lung cancer. SCLC: small cell
lung cancer.
Statistically significant differences (p < 0.001, with the exception of stage with p = 0,036).
SCC: squamous cell carcinoma, ADC: adenocarcinoma, LCUC: Large-cell undifferentiated carcinoma. NSCLC: non small cell lung cancer. SCLC: small cell
lung cancer.
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the literature for this entity [6-8]. Why the remainder
26% of patients were treated with a total dose lower than
60 Gy is unknown. Concomitant RT-CT was applied in
41.7% of the patients with inoperable NSCLC, which canA
Figure 1 Correlations with the radiation rate. Correlation between irrad
and (B) number of radiation oncologists (p = 0.004).be considered a low percentage given the worldwide ac-
ceptance of concomitant RT-CT as standard treatment
option in these cases [6-8,28].
Almost all (97%) of the patients with SCLC who were
treated with radical intent received doses ≥45 Gy, andB
iation rate and (A) number of radiotherapy treatment units (p > 0.05)
Table 7 Comparison with data from VARA-I
Dose (%) Associated CT (%) Stage (%) Intent (%)
VARA′04 VARA′07 VARA′04 VARA′07 VARA′04 VARA′07 VARA′04 VARA´07
NSCLC R <60 Gy 147 (77.4) 136 (27.5) No 106 (25.9) 189 (31) NSCLC I/II/III 332 (90) 415 (84) NSCLC R 212 (63.1) 274 (55.4)
≥60 Gy* 43 (22.6) 358 (72.5) Yes** 303 (74.1) 421 (69) IV# 37 (10) 79 (16) P## 124 (36.9) 220 (44.6)
SCLC R <45 Gy 33 (54.1) 1 (1.2) SCLC LS 54 (79.1) 82 (71) SCLC R 54 (79.1) 82 (71)
≥45 Gy* 28 (45.9) 115 (98.8) ES§ 14 (20.9) 34 (29) P§ 14 (20.9) 34 (29)
Age (years)§ Gender (%) ECOG (%) Radiation rate (%)*
VARA′04 VARA′07 VARA′04 VARA′07 VARA′04 VARA´07 VARA´04 VARA′07
64,6 ± 10,7 66 ± 10 ♀ 33 (8) 55 (9) 0 §§ 94 (39.8) 141 (43.9) 416 (16) 610 (20)
♂ ^ 383 (92) 555 (91) 1 85 (36) 131 (40.7)
2 36 (15.3) 40 (12.5)
3 18 (7.6) 7 (2.2)
4 3 (1.3) 2 (0.7)
NSCLC: non small cell lung cancer. SCLC: small cell lung cancer. LS: limited stage. ES: extended stage. R: radical. P: Palliative.
Differences: *p < 0.01; **p = 0.08; #p = 0.011; ##p = 0.028; §p > 0.1; §§p = 0.02; ^p = 0.54.
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been published on the benefits of early RT administra-
tion in this situation [11]. Among various RT schedules
used to treat LC with palliative intent, the most frequent
was 300 cGy × 10 fractions. Differences in the schedules
used are probably related to the different localizations of
the sites under treatment.
Using a benchmark approach, Barbera L. et al. [29] esti-
mated that initial RT was warranted in 49.3% of LC
patients, and similar conclusions were reached by other au-
thors using different study methods [30,31]. The European
ESTRO QUARTS project [32] recommended RT in up to
61% of LC patients. In the present survey, the irradiation
rate was 20%, 4% higher than recorded in our region in
2004 (17% relative increase) but still low according to the
estimated radiation rate, resulting in an underuse of RT for
lung cancer [33].
We observed major and statistically significant varia-
tions among the eight provinces in the histology and stageTable 8 Comparison with other published data
Study Age Gender (%) Hist
♂ ♀ SCC ADC
Salmerón 2012 [18] 67 90 10 37 20
Escuín 2009 [19] 70 - - 38 -
Prim 2010 [20] 67 93 7 39 19
Escuín 2006 [21] 68 89 11 79 CPNCP
Hernández 2004 [22] 68 85 15 38 17
Santos-M 2005 [23] 67 89 11 33 30
Estrada 2007 [24] 67 90 10 24 17
Alonso-F 2005 [25] 67 92 8 58 29
VARA-II 66 91 8 37 17
SCC: squamous cell carcinoma, ADC: adenocarcinoma, LCUC: Large-cell undifferenti
extended stage.of the disease and in RT intent, fractionation, associated
CT (all p <0.05), and irradiation rate (p < 0.001).
The few studies that addressed VMP in the context of
RT reported variations in medical practice and the
underutilization of RT for LC [10,11,14,34]. The initial arti-
cles by J E Wennberg on VMP [12,13] systematized the
possible causes of differences as follows:
1. Demand: clinical stage, histology, incidence, age, delay
and distance from the hospital… couldn‘t explain this
variability according to our results. Socio-economic
differences were not analyzed in this study [35], how-
ever the Andalusian health system is a public system
with universal free coverage. Patient support system is
another important factor but, considering the public
health system of Andalusia, we believe that the contri-
bution of this factor would be minimal.
2. Service offer: accessibility. If epidemiological causes
are ruled out, resource gaps or limitations may inology (%) Stage (%)
LCUC SCLC I II III IV LS ES
8 16 - - - - - -
- 20 - - - - - -
10 20 10 9 34 47 31 69
21 20 4 37 35 37 61
12 30 - - - - - -
4 13 21 35 42 44 55
29 19 24 4 27 41 - -
5 19 27 7 35 31 47 53
15 19 4 8 61 26 71 29
ated carcinoma. SCLC: small cell lung cancer. LS: limited stage. ES:
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study, a lower irradiation rate was significantly
correlated with a smaller number of radiation
oncologists. In 2007, a mean of 4.2 megavoltage
units were available per million inhabitants, and the
treatment started a median of 41 days after it was
ordered, with significant differences among
hospitals.
3. Style of practice: medical practice patterns may
explain the low irradiation rates found in our region
[36,37]. Most clinical trials have a control arm with
standard treatment that does not include RT [38,39].
In many cases, the variability detected in RT intent, frac-
tionation, and associated CT may be attributable to differ-
ences in styles of professional practice. There is increasing
evidence that unexplained variations in practice are wide-
spread in oncology in general. However, the problem is
not confined to oncology; it should be taken into account
that RT programs maintain unusually good records, and
the excellence of the information systems makes variations
in practice highly visible [10].
Our results weren’t different from other published
data and some differences (such as stage) can be due to
our study only collecting patients treated with initial
radiotherapy.
Regarding VARA-I, radiation rate, administered total
dose, advanced stage and radiotherapy with palliative in-
tent have increased. Thus, we can say that, although we
have more confidence to give more total dose, the radi-
ation rate has increased due to radiotherapy adminis-
tered with palliative intent.
One study limitation is its retrospective and hospital
population-based design, which means that the total
number of patients irradiated for LC may be underesti-
mated, because the patients who were treated in private
centers and patients who might have travelled out of
Andalusia weren’t collected. However, mobility inter-
regions is an uncommon situation in our area, only 10%
of the total care is delivered in private centers, and
the data observed were consistent with the findings of
the previous survey (VARA I) 3 years earlier and the
descriptive analysis and the results obtained weren’t dif-
ferent from other published data. Other important limi-
tation is the time between the year of the study (2007)
and its publication (2013). Nowadays the health system
is probably different regarding 2007. This is a common
fact among the population study. However between
VARA-I and VARA-II (period of time of three years) the
situation was not very different. New techniques of treat-
ment, as stereotactic body radiotherapy, are being imple-
mented now, and no many centers have this technology.
Therefore, our study can reflect very accurate picture of
the use of RT in our health area.Conclusions
Although our results were in agreement with other pub-
lished data and the irradiation rate has increased, this
study shows some variability in care patterns for LC in
our region. The irradiation rate significantly differs among
the provinces and is correlated with the inter-provincial
distribution of radiation oncologists. Significant inter-
hospital differences were detected in the histology and
stage of LC and in its management (RT intent, fraction-
ation, and associated CT). According to the literature, var-
iations in medical practice and underuse of RT are a
worldwide problem that needs to be study and this re-
search is an example of this. It is necessary to examine
variations in practice and distinguish those that are appro-
priate from those that are not justified and must be
eliminated.
Abbreviations
LC: Lung Cancer; NSCLC: Non-Small Cell Lung Cancer; CT: Chemotherapy;
RT: Radiotherapy; SCLC: Small Cell Lung Cancer; VMP: Variability in Medical
Practice; VARA: Variability and Appropriateness of Radiotherapy in Andalusia;
ECOG: Eastern Cooperative Oncology Group.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
IT participated in the quality control of data and algorithms, data analysis
and interpretation, statistical analysis, manuscript preparation, manuscript
editing and manuscript review. JE carried out the study concepts, study
design, quality control of data and algorithms, data analysis and
interpretation and manuscript review. JJ participated in the study concepts,
study design and data acquisition. EA carried out the study concepts, study
design and data acquisition. MM participated in data acquisition and
analysis, interpretation and manuscript review. RG participated in data
acquisition and analysis, interpretation and manuscript review. JPA reviewed
the manuscript and participated in the data analysis. DR participated in the
data analysis and interpretation, statistical analysis, manuscript preparation,
manuscript editing and manuscript review. All authors read and approved
the final manuscript.
Acknowledgements
The authors gratefully acknowledge scientific and technical assistance
provided by Richard Davies. Dr J.P. Arrebola is currently receiving a
postdoctoral contract from the Consejería de Igualdad, Salud y Políticas
Sociales, Junta de Andalucía (RH-0092-2013). The results would not have
been achieved without the selfless collaboration of the staff involved in the
data acquisition: Amalia Palacios (Reina Sofía University Hospital, Córdoba);
Eloisa Bayo (Juan Ramón Jiménez Hospital, Huelva); José Antonio Sánchez
Calzado (Virgen Macarena University Hospital, Sevilla); Mª José Ortiz (Virgen
del Rocío University Hospital, Sevilla); Ismael Herruzo Cabrera (Carlos Haya
University Hospital, Málaga); José Antonio Medina (Virgen de la Victoria
University Hospital, Málaga); Francisco Peracaula 8Punta Europa Hospital,
Cádiz).
Funding
This work was supported by the Public Health System of Andalusia (Grant
number 0266/2007). The funding body did not have influence on the results.
Author details
1Radiation Oncology Department, Virgen de las Nieves Universitary Hospital,
Granada, Spain. 2Institute of Oncology, Cartuja, Sevilla, Spain. 3Radiation
Oncology Department, Puerta del Mar Universitary Hospital, Cádiz, Spain.
4CIBER en Epidemiología y Salud Pública (CIBERESP), Granada, Spain.
Tovar et al. BMC Cancer 2014, 14:697 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/697Received: 6 July 2013 Accepted: 18 September 2014
Published: 23 September 2014References
1. Halpering EC, Perez CA, Brady LW: Principles and Practice of radiation
Oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.
2. Abente L: La Situación del Cáncer en España. Instituto de Salud Carlos III.
Madrid: Ministerio de Sanidad y Consumo; 2005.
3. Sánchez de Cos J: LC in Spain. Current Epidemiology, Survival, and
Treatment. Arch Bronconeumol 2009, 45(7):341–348.
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: Lung cancer.
In AJCC Cancer Staging Manual. 7th edition. Edited by American Joint
Committee on Cancer (AJCC). New York: Springer-Verlag; 2010:299–323.
5. Rubin P: Clinical Oncoly. A multidisciplinary approach for physicians and
students. Philadelphia: WB Saunders Co.; 2001.
6. American College of Chest Physicians (ACCP): The LC Guideline. (2th
edition). Chest 2007, 132(Suppl 3):1–328.
7. Cottish Intercollegiate Guideline Network: Management of patients with
LC. A national clinical guideline. Scotland, United Kingdom: Scottish
Intercollegiate Guideline Network. 2005. [http://www.sign.ac.uk/pdf/
sign80.pdf]
8. National Institute for Health and Clinical Excellence (NICE): The diagnoses
and treatment of Lung Cancer (CG 121). [http://guidance.nice.org.uk/
cg121]
9. DeVita VT, Hellman S, Rosemberg SA: Cáncer. Médica Panamericana:
Principios y Prácticas de Oncología. Madrid; 2000.
10. Mackillop WJ, Dixon P, Zhou Y, Ago CT, Ege G, Hodson DI, Kotalik JF,
Lochrin C, Paszat L, Harris D: Variation in the management and outcome
of non-small cell lung cancer in Ontario. Radiother Oncol 1994,
32(2):106–115.
11. Kepka L, Danilova V, Saghatelyan T, Bajcsay A, Utehina O, Stojanovic S,
Yalman D, Demiral A, Bondaruk O, Kuddu M, Jeremic B, International Atomic
Energy Agency (IAEA): Resources and management strategies for the use
of radiotherapy in the treatment of lung cancer in Central and Eastern
European countries: results of an International Atomic Energy Agency
(IAEA) survey. Lung Cancer 2007, 56(2):235–245.
12. Wennberg JE, Gittelsohn AM: Variations in medical care among small
areas. Sci Am 1982, 264:100–111.
13. Wennberg JE, Gittelsohn AM: A small area variations in health care
delivery. A population-based health information system can guide
planning and regulatory decision-making. Science 1973, 18:1.102–1.108.
14. Jaén J, Alonso E, Expósito J, de las Peñas MD, Cabrera P: Evidence-based
estimation and radiotherapy utilization rate in Andalusia. Clin Translat
Oncol 2007, 9:789–796.
15. National Statistic Institute (NSI). [http//www.ine.es]
16. Granada Cancer Registry (GCR). [http://www.cancergranada.org/en/
granada_cancer_registry_about_us.cfm]
17. American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Manual.
New York, PA: Springer-Verlag; 2002.
18. Salmerón D, Chirlaque MD, Isabel Izarzugaza M, Sánchez MJ, Marcos-
Gragera R, Ardanaz E, Galceran J, Mateos A, Navarro C: Lung cancer
prognosis in Spain: The role of histology, age and sex. Respir Med 2012,
106:1301–1308.
19. Escuín JS: Lung cancer in Spain. Current Epidemiology, Survival, and
Treatment. Arch Bronconeumol 2009, 45(7):341–348.
20. Prim JM, Barcala FJ, Esquete JP, Reino AP, López AF, Cuadrado LV: Lung
cancer in a health area of Spain: incidence, characteristics and survival.
Eur J Cancer Care 2010, 19(2):227–233.
21. Sánchez de Cos Escuín J, Miravet Sorribes L, Abal Arca J, Núñez Ares A,
Hernández Hernández J, Castañar Jover AM, Muñoz Gutiérrez FJ, García
Arangüena L, Alonso MA, Montero Martínez MC, Allende González J,
Sánchez Hernández I: Estudio multicéntrico epidemiológico-clínico de
cáncer de pulmón en España (estudio EpicliCP-2003). Arch Bronconeumol
2006, 42(9):446–452.
22. Hernández Hernández JR, del Pozo JA T, Moreno Canelo P, Rodríguez
Puebla A, Paniagua Tejo S, Sánchez Marcos JC: Incidencia del cáncer de
pulmón en la provincia de Ávila. Año 2002 y tendencias en una década.
Arch Bronconeumol 2004, 40(7):304–310.
23. Santos-Martínez MJ, Curull V, Blanco ML, Macià F, Mojal S, Vila J, Broquetas
JM: Lung cancer at a University Hospital: epidemiological andhistological characteristics of a recent and a historical series.
Arch Bronconeumol 2005, 41(6):301–312.
24. Estrada Trigueros G, Comeche L, López Encuentra A, Montoro Zulueta J,
González Garrido F, Colina F: Carcinoma broncogénico 2000–2001:
características y supervivencia global. Arch Bronconeumol 2007,
43(11):594–598.
25. Alonso-Fernández MA, García-Clemente M, Escudero-Bueno C: Características
del carcinoma broncopulmonar en una región del norte de España.
Arch Bronconeumol 2005, 41(9):478–483.
26. Alberg AJ, Ford JG, Samet JM: Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest 2007,
132(Suppl 3):29–55.
27. Janssen-Heijnen ML, Coebergh JW: The changing epidemiology o lung
cancer in Europe. Lung Cancer 2003, 41(3):245–258.
28. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M,
Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G,
Owen J: Radiotherapy patterns of care study in lung carcinoma.
J Clin Oncol 2003, 21:453–459.
29. Barbera L, Zhang-Salomon J, Huang J, Tyldesley S, Mackillop W: Defining
the need for radiotherapy for lung cancer in the general population. A
criterion-based, benchmarking approach. Medical Care 2003,
41(9):1074–1085.
30. Tyldesley S, Delaney G, Foroudi F, Barbera L, Kerba M, Mackillop W:
Estimating the need for radiotherapy for patients with prostate, breast,
and lung cancers: verification of model estimates of need with
radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol
Phys 2011, 1; 79(5):1507–1515.
31. Delaney G, Jacob S, Featherstone C, Barton M: The role of radiotherapy in
cancer treatment: estimating optimal utilization from a review of
evidence-based clinical guidelines. Cancer 2005, 104:1129–1137.
32. Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, van den
Bogaert W: Towards evidence-based guidelines for radiotherapy
infrastructure and staffing needs in Europe: the ESTRO QUARTS project.
Radiother Oncol 2005, 75:355–365.
33. Tovar I, Expósito J, Jaén J, Alonso E: Underuse of radiotherapy in lung
cancer has negative consequences for patients. J Thorac Oncol 2013,
8(1):62–67.
34. Vinod SK, Simonella L, Goldsbury D, Delaney GP, Armstrong B, O'Connell DL:
Underutilization of radiotherapy for lung cancer in New South Wales,
Australia. Cancer 2010, 116(3):686–694.
35. Jack RH, Gulliford MC, Ferguson J, Møller H: Explaining inequalities in
access to treatment in lung cancer. J Eval Clin Pract 2006, 12(5):573–582.
36. Tai P, Yu E, Battista J, Van Dyk J: Radiation treatment of lung cancer–
patterns of practice in Canada. Radiother Oncol 2004, 71(2):167–174.
37. Lee IH, Hayman JA, Landrum MB, Tepper J, Tao ML, Goodman KA, Keating
NL: Treatment recommendations for locally advanced, non-small-cell
lung cancer: the influence of physician and patient factors. Int J Radiat
Oncol Biol Phys 2009, 74(5):1376–1384.
38. Loannidis JPA, Pavlidis N: Levels of Absolute survival benefit for
systematic therapies of advanced cancer: a call for standards. Eur J Canc
2003, 39:1194–1198.
39. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK: First-line chemotherapy
in the treatment of advanced Non-small cell lung cancer. A systematic
review. J Thorac Oncol 2010, 5:260–274.
doi:10.1186/1471-2407-14-697
Cite this article as: Tovar et al.: Pattern of use of radiotherapy for lung
cancer: a descriptive study. BMC Cancer 2014 14:697.
